Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber(NYU Langone Health), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), René González(University of Miami), Javier Sabater(Bristol-Myers Squibb (United States)), Marcus O. Butler(University of Toronto), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Ragini R. Kudchadkar, Michael Smylie(Inserm), Michele Maio(University of Siena), Célèste Lebbé(Inserm), C. Lance Cowey(Texas Oncology), Michael Schenker(Sorbonne Université), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Tae M. Kim(Seoul National University Hospital), Mark R. Middleton(University of Oxford), Michael B. Atkins(Georgetown University), Veerle de Pril(Inserm), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Georgina V. Long(The University of Sydney), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), James Larkin(Trinity College Dublin), Laurent Mortier, Victoria Atkinson(The University of Queensland), Kenji Yokota(International Research Center for Japanese Studies), Helen Gogas(National and Kapodistrian University of Athens), Anila Qureshi(Bristol-Myers Squibb (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Jean-Jacques Grob(Aix-Marseille Université), Naoya Yamazaki(Tokyo National Hospital)
Cited by 2,222
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k